XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Common stock
Additional Paid-In Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020   28,159,000    
Beginning balance at Dec. 31, 2020 $ 161,262 $ 282 $ 470,719 $ (309,739)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of stock on options exercised and restricted stock units vested (in shares)   303,000    
Issuance of stock on options exercised and restricted stock units vested 101 $ 3 98  
Share-based compensation 2,669   2,669  
Tax benefit from share-based compensation (3,439)   (3,439)  
Net income 10,620     10,620
Ending balance (in shares) at Mar. 31, 2021   28,462,000    
Ending balance at Mar. 31, 2021 171,213 $ 285 470,047 (299,119)
Beginning balance (in shares) at Dec. 31, 2020   28,159,000    
Beginning balance at Dec. 31, 2020 161,262 $ 282 470,719 (309,739)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 113,626      
Ending balance (in shares) at Jun. 30, 2021   28,870,000    
Ending balance at Jun. 30, 2021 276,687 $ 289 472,511 (196,113)
Beginning balance (in shares) at Mar. 31, 2021   28,462,000    
Beginning balance at Mar. 31, 2021 171,213 $ 285 470,047 (299,119)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of stock on options exercised and restricted stock units vested (in shares)   408,000    
Issuance of stock on options exercised and restricted stock units vested 4 $ 4    
Share-based compensation 2,586   2,586  
Tax benefit from share-based compensation (122)   (122)  
Net income 103,006     103,006
Ending balance (in shares) at Jun. 30, 2021   28,870,000    
Ending balance at Jun. 30, 2021 276,687 $ 289 472,511 (196,113)
Beginning balance (in shares) at Dec. 31, 2021   28,830,000    
Beginning balance at Dec. 31, 2021 319,541 $ 288 477,829 (158,576)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of stock on options exercised and restricted stock units vested (in shares)   419,000    
Issuance of stock on options exercised and restricted stock units vested 4 $ 4    
Repurchases of common stock (in shares)   (269,000)    
Repurchases of common stock (15,196) $ (2)   (15,194)
Share-based compensation 3,141   3,141  
Tax benefit from share-based compensation (10,298)   (10,298)  
Net income 36,066     36,066
Ending balance (in shares) at Mar. 31, 2022   28,980,000    
Ending balance at Mar. 31, 2022 333,258 $ 290 470,672 (137,704)
Beginning balance (in shares) at Dec. 31, 2021   28,830,000    
Beginning balance at Dec. 31, 2021 319,541 $ 288 477,829 (158,576)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 57,286      
Ending balance (in shares) at Jun. 30, 2022   28,501,000    
Ending balance at Jun. 30, 2022 335,028 $ 285 473,696 (138,953)
Beginning balance (in shares) at Mar. 31, 2022   28,980,000    
Beginning balance at Mar. 31, 2022 333,258 $ 290 470,672 (137,704)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of stock on options exercised and restricted stock units vested (in shares)   36,000    
Issuance of stock on options exercised and restricted stock units vested 0 $ 0    
Repurchases of common stock (in shares)   (515,000)    
Repurchases of common stock (22,474) $ (5)   (22,469)
Share-based compensation 3,295   3,295  
Tax benefit from share-based compensation (271)   (271)  
Net income 21,220     21,220
Ending balance (in shares) at Jun. 30, 2022   28,501,000    
Ending balance at Jun. 30, 2022 $ 335,028 $ 285 $ 473,696 $ (138,953)